摘要
目的 探究利伐沙班与达比加群酯在高龄非瓣膜病性房颤(NVAF)患者长期抗凝治疗中的应用效果与安全性。方法 选取2019年2月至2020年2月阳江市阳东区人民医院收治的100例高龄NVAF患者为研究对象,采用随机数字表法分为治疗A组与治疗B组,每组50例。治疗A组采用利伐沙班治疗,治疗B组采用达比加群酯治疗,随访12个月,比较两组治疗前后肝肾功能及治疗期间有效性终点与安全性终点情况。结果 两组治疗前后肌酐、尿素氮、转氨酶、三酰甘油、总胆红素水平比较差异无统计学意义;治疗A组发生栓塞事件1例(2.00%),治疗B组发生栓塞事件2例(4.00%),两组有效性比较差异无统计学意义。治疗A组发生出血事件7例(14.00%),治疗B组发生出血事件6例(12.00%),两组安全性比较差异无统计学意义。结论 利伐沙班与达比加群酯在高龄NVAF长期抗凝治疗中有效性与安全性相当,对肝肾功能影响无明显差异,临床可根据患者具体情况用药。
Objective To explore the efficacy and safety of rivaroxaban and dabigatran etexilate in long-term anticoagulation therapy in elderly patients with non-valvular atrial fibrillation(NVAF). Methods A total of 100 elderly NVAF patients who were admitted to the People’ s Hospital of Yangdong District, Yangjiang City from February 2019 to February 2020 were selected as the research subjects, and they were divided into treatment group A and treatment group B, with 50 cases in each group. The treatment group A was treated with rivaroxaban, and the treatment group B was treated with dabigatran etexilate. Follow-up was 12 months, the liver and kidney functions before and after treatment and the efficacy and safety endpoints during treatment were compared between two groups. Results There was no statistically significant difference in the levels of creatinine, urea nitrogen, transaminase, triacylglycerol, and total bilirubin between the two groups before and after treatment;there was 1 case of embolism event in treatment group A(2.00%), treatment group B embolism occurred in 2 cases(4.00%), and there was no significant difference in effectiveness between the two groups. There were 7 bleeding events(14.00%) in treatment group A and 6 bleeding events(12.00%) in treatment group B, there was no significant difference in safety results between the two groups. Conclusion Rivaroxaban and dabigatran etexilate are equivalent in effectiveness and safety in long-term anticoagulation treatment of elderly NVAF, and there is no significant difference in the effects of liver and kidney function, clinical medication can be based on the specific situation of the patient.
作者
梅圆圆
梁羡方
梁健平
MEI Yuanyuan;LIANG Xianfang;LIANG Jianping(Yangdong District People's Hospital of Yangjiang City,Yangjiang,Guangdong,529500,China)
出处
《当代医学》
2022年第20期34-36,共3页
Contemporary Medicine
关键词
利伐沙班
达比加群酯
高龄
非瓣膜病性房颤
抗凝治疗
Rivaroxaban
Dabigatran etexilate
Advanced age
Non-valvular atrial fibrillation
Anticoagulation therapy
